{"id":"sb-275833-ointment-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Local skin atrophy"},{"rate":null,"effect":"Skin irritation or burning"},{"rate":null,"effect":"Folliculitis"}]},"_chembl":{"chemblId":"CHEMBL2108523","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a glucocorticoid receptor agonist applied topically, SB-275833 suppresses local inflammatory cytokine production and immune cell infiltration in affected skin tissue. The 1% ointment formulation allows direct delivery to dermatological lesions, minimizing systemic exposure while maximizing local anti-inflammatory efficacy.","oneSentence":"SB-275833 is a topical corticosteroid that reduces inflammation and immune response in skin conditions.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:33:35.916Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory skin conditions (specific indication not publicly detailed in phase 3)"}]},"trialDetails":[{"nctId":"NCT01591785","phase":"NA","title":"Treatment of Staphylococcus Aureus Colonization in Hand Eczema","status":"COMPLETED","sponsor":"Gary Goldenberg","startDate":"2012-01","conditions":"Hand Eczema, Foot Eczema","enrollment":60},{"nctId":"NCT03304873","phase":"PHASE3","title":"Retapamulin as a Decolonizing Agent for MRSA","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2017-12-01","conditions":"MRSA","enrollment":47},{"nctId":"NCT00856089","phase":"PHASE4","title":"Efficacy Study of Altabax to Clear Methicillin-resistant Staphylococcus Aureus (MRSA) Nasal Colonization","status":"WITHDRAWN","sponsor":"Ochsner Health System","startDate":"2009-05","conditions":"Methicillin-resistant Staphylococcus Aureus","enrollment":""},{"nctId":"NCT00852540","phase":"PHASE3","title":"Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-04","conditions":"Skin Infections, Bacterial","enrollment":410},{"nctId":"NCT00903279","phase":"PHASE2","title":"Treatment of Patients Colonized With Methicillin-Resistant Staphylococcus Aureus Prior to Bone and Joint Surgery","status":"WITHDRAWN","sponsor":"Bay Pines VA Healthcare System","startDate":"2009-08","conditions":"Orthopedic Procedures, Methicillin-resistant Staphylococcus Aureus","enrollment":""},{"nctId":"NCT00133874","phase":"PHASE3","title":"Topical SB-275833 Ointment, 1% For The Treatment Of Impetigo","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-04","conditions":"Skin Infections, Bacterial","enrollment":520},{"nctId":"NCT00555061","phase":"PHASE4","title":"Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-09","conditions":"Skin Infections, Bacterial","enrollment":60},{"nctId":"NCT00539994","phase":"PHASE2","title":"Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Aureus","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-09","conditions":"Infections, Bacterial","enrollment":57},{"nctId":"NCT00684177","phase":"PHASE3","title":"Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-05","conditions":"Skin Infections, Bacterial","enrollment":508},{"nctId":"NCT00133848","phase":"PHASE3","title":"Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-04","conditions":"Impetigo","enrollment":210},{"nctId":"NCT01064947","phase":"PHASE4","title":"Safety and Efficacy Study of Altabax Ointment in the Treatment of Secondarily Infected Atopic Dermatitis","status":"COMPLETED","sponsor":"Derm Research, PLLC","startDate":"2010-02","conditions":"Atopic Dermatitis, Secondary Infection","enrollment":29},{"nctId":"NCT01397461","phase":"PHASE3","title":"Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo","status":"COMPLETED","sponsor":"Ferrer Internacional S.A.","startDate":"2012-03","conditions":"Impetigo","enrollment":465},{"nctId":"NCT01126268","phase":"PHASE4","title":"Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2010-04","conditions":"Impetigo, Folliculitis, Secondarily Infected Eczema","enrollment":38},{"nctId":"NCT00871208","phase":"PHASE4","title":"Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Low-Potency Corticosteroids Versus Low-Potency Corticosteroid Mono-therapy","status":"WITHDRAWN","sponsor":"St. Luke's-Roosevelt Hospital Center","startDate":"2009-05","conditions":"Atopic Dermatitis","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SB-275833 ointment","1%"],"phase":"phase_3","status":"active","brandName":"SB-275833 ointment, 1%","genericName":"SB-275833 ointment, 1%","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SB-275833 is a topical corticosteroid that reduces inflammation and immune response in skin conditions. Used for Inflammatory skin conditions (specific indication not publicly detailed in phase 3).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}